Chapter 1404

If you want to talk about the northern United pharmaceutical industry, it still has some value.

Tens of thousands of mu of land has just been acquired. For the time being, tens of thousands of skilled workers can not be simply regarded as a burden. They are all skilled workers.

However, the reality is that there was no shortage of skilled workers in China in the 1980s. So many workers in the small, third, and large third tier industries are going to lose their jobs. If it wasn't for the establishment of the chemical and pharmaceutical revitalization office and the northern United pharmaceutical industry, ten thousand workers in the North China pharmaceutical industry would face unemployment in a few years.

To be more precise, tens of thousands of workers are mixed together, just like a pile of unsorted jujubes. If they don't spread out, the rotten jujubes will bring the good ones to rot sooner or later.

No one would have thought that such a northern United pharmaceutical could be valued at US $60 million and then receive real money from Jericho.

They are not interested in Jielikang, whether it is the northern United pharmaceutical industry or the chemical and pharmaceutical revitalization office. The only thing they are interested in is the drugs in Yang Rui's hands.

Just the profits from production and sales can make them earn back their capital.

Only the new drugs developed by Yang Rui can bring them back $30 million.

The desire of pharmaceutical companies for new drugs is difficult for workers in other industries to realize.

There are thousands of pharmaceutical companies in the world, and the number of pharmaceutical companies with the ability to develop new drugs is usually less than 100. Except for the single digit generic drug companies, the remaining two digit pharmaceutical companies can only put three or five pure new drugs into the market every year.

At this time, who is in charge of the new drug is in charge of life and death.

Either symbolically or practically, the power of life and death.

Like Gaucher disease, although it is a rare disease, it is also a rare disease with high incidence rate. The number of patients worldwide is one hundred thousand. However, without suitable drugs, the life cycle of Gaucher's disease is 10 years, and it will not exceed 20 years.

At this time, there is a message that everyone is not willing to think about. If there is a specific medicine, there will not be only hundreds of thousands of Gaucher patients in the world.

And so many people, obviously can't get the medicine at one time.

Even from the perspective of safety, countries will not let new drugs spread at home.

At this time, pharmaceutical companies are in charge of the life and death of these patients.

In which country they apply for sales first, patients in which country can get treatment in advance, which not only means higher survival rate, but also means reducing pain and improving quality of life.

No one wants to drag a sick body to live.

From the perspective of consumers and hospitals, they also expect the emergence of specific drugs.

Pharmaceutical companies that can always produce new drugs and good drugs will be more popular with hospitals and doctors. This is the only thing that belongs to pharmaceutical companies. When necessary, pharmaceutical companies can even bundle sales, stipulating that as many specific drugs as they buy, they should buy as many common drugs

Where laws and regulations are not strict, whoever holds the power of life and death is entitled to make money.

50 How much is ten thousand lives worth?

Is it more than $100 per person?

Is 200 dollars per person expensive?

In the modern consumption system, the production cost is only a small head for pharmaceutical companies, and the cost of sales, R & D and management is the most expensive place.

A new drug may not make a pharmaceutical company rich all at once. After all, there are few blockbusters with annual sales of 1 billion US dollars. However, a steady stream of new drugs is the meaning of the survival of pharmaceutical companies.

It is not only the significance of the survival of pharmaceutical companies, but also the public, society and the state's views on it.

If a pharmaceutical company can't produce a new drug in five years, no matter whether it makes it or buys it, even if it earns a lot in other income, investors will always worry about it.

If a pharmaceutical company can't produce a new drug in 10 years, even if the investors don't say it, the company will not be able to survive.

In the business of selling health and life, pharmaceutical companies have too many ways to make money.

The annual treatment cost of some special rare drugs can even reach one million dollars, which can be called abnormal. Pharmaceutical companies in war-torn areas have never been benevolent. Pharmaceutical companies in prosperous cities are good at doing business.

However, no matter how pharmaceutical companies want to make money, you have to have drugs in your hands first.

15 New drugs with a patent period of 25 years and rare drugs with a patent period of 25 years are the weapons in the hands of pharmaceutical companies.As much as a 15-year-old boy is willing to pay for his rogue weapon, a pharmaceutical company is willing to pay for a new drug.

Northern United pharmaceutical's careful thinking, under the pressure of Jielikang, such as ice and snow fell on the oven, disappeared in an instant.

However, the funds allocated to the ion channel laboratory in advance are still only 200000 US dollars.

In the words of Wang Gaohan, the new general manager of North United Pharmaceutical Co., Ltd., "use it first, if it's not enough, say hello again, and the money will come."

Naturally, the project team responsible for recombinant DNA was full of complaints. Gu Qiang even complained: "200000 US dollars is not enough to buy a fluorescence microplate reader. It's over without starting."

Yang Rui's choice of specific drug for Gaucher's disease is enzyme replacement scheme. It is such a simple principle to supplement enzyme for people who lack enzyme.

However, it is extremely difficult to make human brain glucosidase - no matter how this step is carried out, instruments such as fluorescent microplate reader are necessary.

Human eyes can't see glucocerebrosidase.

In addition, higher resolution UV-Vis spectrophotometer, more efficient new electrophoresis instrument and so on, are also essential expenses.

Although laboratories can share these commonly used equipment, it is obviously not a right choice in the tight time of new drug development.

In addition, the scale of ion channel laboratory is expanding day by day. To develop new projects, it is necessary to add new instruments, even repetitive instruments. It's like the simplest microscope. You can't have a bunch of dogs waiting in line to use it.

Some domestic project teams are very poor. Yang Rui is not going to let the ion channel laboratory live the hard life of queuing up for instruments at two o'clock in the morning.

Who loves who is in the past.

"Take the money from the lab's general ledger and give them back 200000 dollars." Yang Rui quickly made a decision, and then called Xu Zhengping and said, "you should contact a foreign evaluation company to evaluate the price of our current recombinant DNA project team's alternatives to glucocerebrosidase."

"What's that?" Xu Zhengping was stunned.

"It's to find a foreigner's company and let them see how much our project team is worth in the market." Yang Rui pause for a moment, said: "the people of northern United pharmaceutical industry are used to the life of state-owned enterprises, and they still want to get the research results at the cost price. 200000? Two million is just a head up. "

Xu Zhengping hesitated to find out. He didn't know how much pressure Yang Rui's decision exerted on northern United pharmaceutical industry. In fact, there are few domestic enterprises that can realize this.

In this era when research institutes were set up under enterprises, the value of research results always fluctuated by cost price.

Unfortunately, Yang Rui is not ready to discuss the cost with them.

How much cost is my business, and the price is determined by the value.